Thanks Ross. 2022 is off to a solid start with net operating income of $875,000 continued profitability and adjusted EBITDA of $1.1 million. As we kick off the year we believe our industry is transitioning away from some of the pandemic related headwinds we've seen during the past two years. With our diverse revenue streams, we believe we're well-positioned in both our financial assets division and our industrial assets division to capitalize on anticipated tailwinds and more favorable market conditions. Looking at the two segments; net operating income in the industrial assets division was $846,000 in the first quarter of 2022 as compared to $1.3 million in the first quarter of 2021. Within our financial assets division, we saw a significant growth resulting in net operating income of $731,000, an increase of 59% as compared to $461,000 in the first quarter of 2021. Sequentially net operating income in the financial assets division grew 12% as compared to the fourth quarter of 2021. On a consolidated basis, net operating income was $875,000 compared to $1 million in the first quarter of 2021. Net income was $645,000 or $0.02 per diluted share compared to net income of $1 million or $0.03 per diluted share in the first quarter of 2021. We achieved EBITDA of $1 million as compared to EBITDA of $1.1 million in the same quarter last year. And adjusted EBITDA was $1.1 million for the first quarter of 2022 compared to $1.5 million in the first quarter of 2021. We also continue to pursue strategic real estate opportunities which has proven to be a very profitable aspect of our business. With our visibility today, we anticipate closing our two remaining Huntsville real estate transactions in Q2 or Q3 which are expected to contribute more than $2.5 million and combined net profit. In addition, and subsequent to the close of the quarter, we announced that we have entered into a partnership that has acquired two pharmaceutical plants in St. Louis, Missouri. We anticipate that the sale of these facilities will follow a similar model to that of our successful Huntsville partnership. At March 31, 2022, we had aggregate tax net operating loss carry forwards of approximately $78 million, including 62 million of unrestricted net operating tax losses, and approximately $16 million of restricted net operating tax losses. Substantially all of the net operating loss carry forwards expire between 2024 and 2037. We believe that the considerable amount of loss carry forward will prove to be a valuable asset to the company as we continue to generate positive and upward results. Finally, our balance sheet remains strong with stockholders equity of $33 .4 million as of March 31, 2022 compared to $32.6 million as of December 31, 2021 and networking capital of $8.8 million. With that, I'll now turn the call back over to Ross.